CLDX•benzinga•
Celldex Launches Phase 2 Study Of Barzolvolimab For Atopic Dermatitis, Targeting Mast Cell-Driven Inflammation And Epithelial Barrier Dysfunction With Patient Enrollment Underway
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 19, 2024 by benzinga